These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 31535640)

  • 1. Stem cell therapy for Parkinson's disease: safety and modeling.
    Stoddard-Bennett T; Pera RR
    Neural Regen Res; 2020 Jan; 15(1):36-40. PubMed ID: 31535640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
    Stoddard-Bennett T; Reijo Pera R
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standards for Deriving Nonhuman Primate-Induced Pluripotent Stem Cells, Neural Stem Cells and Dopaminergic Lineage.
    Yang G; Hong H; Torres A; Malloy KE; Choudhury GR; Kim J; Daadi MM
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30227600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using iPS Cells toward the Understanding of Parkinson's Disease.
    Torrent R; De Angelis Rigotti F; Dell'Era P; Memo M; Raya A; Consiglio A
    J Clin Med; 2015 Mar; 4(4):548-66. PubMed ID: 26239346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What we can learn from iPSC-derived cellular models of Parkinson's disease.
    Caiazza MC; Lang C; Wade-Martins R
    Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients.
    Osborn TM; Hallett PJ; Schumacher JM; Isacson O
    Front Cell Neurosci; 2020; 14():58. PubMed ID: 32317934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.
    Jung YW; Hysolli E; Kim KY; Tanaka Y; Park IH
    Curr Opin Neurol; 2012 Apr; 25(2):125-30. PubMed ID: 22357218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell reprogramming therapy for Parkinson's disease.
    Dong W; Liu S; Li S; Wang Z
    Neural Regen Res; 2024 Nov; 19(11):2444-2455. PubMed ID: 38526281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell therapy for Parkinson's disease with induced pluripotent stem cells].
    Morizane A
    Rinsho Shinkeigaku; 2019 Mar; 59(3):119-124. PubMed ID: 30814448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem Cell-Based Modeling Protocol for Parkinson's Disease.
    Arjmand B; Kokabi-Hamidpour S; Aghayan HR; Alavi-Moghadam S; Arjmand R; Rezaei-Tavirani M; Goodarzi P; Nasli-Esfahani E; Nikandish M
    Methods Mol Biol; 2024; 2736():105-114. PubMed ID: 36749483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases.
    Yefroyev DA; Jin S
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of cell therapies and brain repair: Parkinson's disease leads the way.
    Petit GH; Olsson TT; Brundin P
    Neuropathol Appl Neurobiol; 2014 Feb; 40(1):60-70. PubMed ID: 24372386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.
    Lescaudron L; Naveilhan P; Neveu I
    Curr Med Chem; 2012; 19(35):6018-35. PubMed ID: 22963567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate models.
    Qiu Z; Farnsworth SL; Mishra A; Hornsby PJ
    Stem Cells Cloning; 2013 Jul; 6():19-29. PubMed ID: 24426786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?
    Jacobs BM
    J Parkinsons Dis; 2014; 4(1):15-27. PubMed ID: 24398656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Approaches and Molecular Mechanisms for Directly Reprogramming Fibroblasts Into Neurons and Dopamine Neurons.
    Han F; Liu Y; Huang J; Zhang X; Wei C
    Front Aging Neurosci; 2021; 13():738529. PubMed ID: 34658841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cells for modeling neurological disorders.
    Russo FB; Cugola FR; Fernandes IR; Pignatari GC; Beltrão-Braga PC
    World J Transplant; 2015 Dec; 5(4):209-21. PubMed ID: 26722648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.